疫苗相关增强疾病:病例定义及免疫安全数据收集分析呈现指南
本文为布莱顿协作组织(Brighton Collaboration)制定的「疫苗相关增强疾病」病例定义,用于免疫接种后不良事件评价。该定义由流行病防范创新联盟(CEPI)召集的专家组制定,在SARS-CoV-2等新发病原体疫苗研发背景下,遵循布莱顿协作组织格式,经文献 exhaustive 综述和专家咨询形成共识定义及确定性分级。
要点
- 提供疫苗相关增强疾病的标准化病例定义及确定性分级。
- 适用于免疫接种后不良事件的评价与数据收集。
- 由CEPI召集专家组制定,经同行评审。
核心结论
- 布莱顿协作组织制定了疫苗相关增强疾病的共识病例定义及确定性分级,用于免疫安全数据评价。
研究设计与样本
- 由CEPI召集的专家组制定,遵循布莱顿协作组织病例定义格式,经文献 exhaustive 综述和专家咨询形成共识,并经同行评审。
关键数值与推荐
- 提供了疫苗相关增强疾病的病例定义及定义的确定性水平。
临床怎么用
- 可用于免疫接种后不良事件的标准化评价和数据收集分析呈现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This is a Brighton Collaboration Case Definition of the term "Vaccine Associated Enhanced Disease" to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission.
引用
- Munoz FM, Cramer JP, Dekker CL, et al. Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021. PMID: 33637387. doi:10.1016/j.vaccine.2021.01.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。